Agoracom

VANCOUVER, British Columbia, Jul 10, 2007 -- ProtoKinetix Inc. (OTCBB: PKTX) announces the results of extensive testing of the storage of blood platelets done by the Etablissement Francais du Sang-Alsace (EFS). This prestigious blood specialty institution is affiliated with the Louis Pasteur University in Strasbourg and provides one of the world's premier research facilities in the field of hematology. The collaborative project was headed up by EFS Director, Professor Jean-Louis Cazanave, one of the leading authorities in hematology.

Currently blood platelets are stored at the high temperature of 22 degrees C. This temperature allows for bacterial contamination which means that after a maximum of 4 1/2 - days they have to be discarded. Storage at lower temperatures is extremely desirable but previously impossible because of the activation of the clotting of the platelets.

At the critical temperature of 15 degrees C, blood platelets treated with AAGP(TM) were stored for 21-days with no clotting or coagulation. The untreated control group of platelets had massively aggregated (clotted) by approximately 80%. These findings indicate that blood platelets treated with AAGP(TM) may be able to be stored at refrigeration temperatures having a useful shelf life of 28-days.

Blood platelets are one of the most critical blood products vital for the treatment of all trauma victims to arrest the bleeding. The ability to now provide an adequate supply of platelets for battlefields and emergency medical technicians will dramatically improve the survivability of critical wounds.

About ProtoKinetix:

ProtoKinetix Inc is a Biotechnical Company that has developed and patented a family of synthetic antifreeze glycoproteins (AAGP(TM)) for human and veterinary medicine, the pharmaceutical and cosmetic industries. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is currently negotiating commercial and collaborative agreements on several of the proven and tested applications. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

On behalf of the Board of Directors Company Office: Suite # 1500 885 West Georgia Street Vancouver, BC V6C 3E8

ProtoKinetix Inc.

Blair Henderson,

604-687-9887